Skip to main content

Advertisement

SpringerLink
Log in

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The aim of this study was to determine the antitumor activity of 17-(Allylamino)-17-demethoxyge-ldanamycin (17-AAG), a heat shock protein 90(hsp90) inhibitor in patients with metastatic papillary renal cell carcinoma (RCC) or metastatic clear cell RCC. Eligible patients were divided into 2 cohorts based on histological subtype: papillary or clear cell RCC. All patients had advanced RCC with measurable disease, a Karnofsky performance status of at least 70, and no evidence of brain metastases. Twelve patients with clear cell RCC and 8 patients with papillary RCC were treated with 17-AAG on this phase II trial. 17-AAG was given intravenously at 220 mg/m2 twice weekly for 2 weeks followed by a week of rest. Cycle length was 21 days. No patient in either cohort achieved a complete or partial response. Toxicities included elevated liver function tests, optic neuritis, dyspnea, fatigue, and gastrointestinal side effects. Six of the 20 patients required dose reduction. At the dose and schedule used in this trial, 17-AAG did not achieve objective response in the treatment of clear cell or papillary renal cell carcinoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875

    Article  PubMed  CAS  Google Scholar 

  2. Motzer RJ, Rini, BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukoswki RM, George DJ, Kim ST, Baum CM (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology. vol. 23, Orlando, FL, p 380s

  3. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

    Article  PubMed  CAS  Google Scholar 

  4. Ratain MJE, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O’Dwyer P (2005) Final findings from a phase II placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). American Society of Clinical Oncology. vol. 23, no 16S, Orlando, FL, p 388s

  5. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163–2172

    Article  PubMed  CAS  Google Scholar 

  6. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936–29944

    Article  PubMed  CAS  Google Scholar 

  7. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478–2482

    PubMed  CAS  Google Scholar 

  8. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342–349

    PubMed  CAS  Google Scholar 

  9. Basso AD, Solit DB, Munster PN, Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159–1166

    Article  PubMed  CAS  Google Scholar 

  10. Burger AM, Fiebig HH, Stinson SF, Sausville EA (2004) 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 15:377–387

    Article  PubMed  CAS  Google Scholar 

  11. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078–1087

    Article  PubMed  CAS  Google Scholar 

  12. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885–1893

    Article  PubMed  CAS  Google Scholar 

  13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  14. Stadler WM (2004) Therapeutic options for variant renal cancer: A true orphan disease. Clin Cancer Res 10:6393S–6396S

    Article  PubMed  Google Scholar 

  15. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343–2350

    Article  PubMed  CAS  Google Scholar 

  16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA

    Ellen A. Ronnen, G. Varuni Kondagunta, Suzanne M. Sweeney, John K. DeLuca & Robert J. Motzer

  2. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA

    Lawrence Schwartz

  3. Department of Biostatistics, Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA

    Nicole Ishill & Jennifer Bacik

Authors
  1. Ellen A. Ronnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Varuni Kondagunta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole Ishill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suzanne M. Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John K. DeLuca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lawrence Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jennifer Bacik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Motzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ronnen, E.A., Kondagunta, G.V., Ishill, N. et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24, 543–546 (2006). https://doi.org/10.1007/s10637-006-9208-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-006-9208-z

Keywords

Search

Navigation